To further enhance the Basser Center's mission, the Basser Global Prize was established by Shari Basser Potter and Leonard Potter to honor a visionary scientist who has conceptually advanced BRCA1/2-related research that has led to improvements in clinical care. The prize will be considered for a broad range of basic, translational and clinical BRCA1/2 cancer researchers worldwide. Outstanding candidates will be those whose research has produced seminal advances in the field and who continue to drive BRCA1/2-related research towards the ultimate goal of mitigating the adverse impact of deleterious BRCA1/2 and related mutations.

The Basser Global Prize provides $100,000 in unrestricted support of the awardee's innovative BRCA1/2 related research efforts. The Awardee will give the Keynote address at the annual Basser Center for BRCA Symposium the following year, at which time they will be awarded the Basser trophy and a personal $10,000 cash prize by the Gray and Potter Families.

The Basser Global Prize Application Process

Eligibility
Nominees are not restricted to any geographic area or type of institution. The appropriate Institutional Official (e.g. Chancellor, Dean or Provost) must nominate applicants. Only one nomination per institution will be accepted. Self-nominations will not be accepted.

The following must be included in the nomination package:

  • Basser Global Prize Application Form
  • Nominee and Institutional Official contact information and signatures
  • Investigator Statement with succinct summary of nominee's major BRCA-related research accomplishments with emphasis on how these findings have advanced BRCA-related research, five most important publications related to nominee's BRCA research with a short description of the importance of each publication and nominee's vision for the future of BRCA research including her/his research program over the next five
  • Nominee's CV
  • Nominating letter (1 page). The Institutional Official will describe the major accomplishments of the nominee and why this individual warrants consideration for the Basser Global Prize.

Nominations are due by 5 PM ET on Friday, August 27, 2021. Please address any inquiries to Basserinfo@pennmedicine.upenn.edu.

The 2021 Basser Global Prize Winner

The Basser Center is honored to announce that Andre Nussenzweig, PhD, of the National Cancer Institute (NCI), is the recipient of the ninth annual Basser Global Prize. Dr. Nussenzweig serves as branch chief of the Laboratory of Genome Integrity in the NCI’s Center for Cancer Research. Dr. Nussenzweig’s work on the fundamental aspects of DNA repair, replication, and genome integrity in cells has led to important discoveries that have applications for the development of biomarkers and targeted therapeutics for the treatment of BRCA-mutated cancers. In 2011, Dr. Nussenzweig established a new department at NCI called the Laboratory of Genome Integrity. He is also an elected member of the European Molecular Biology Organization, a National Institutes of Health Distinguished Investigator, and a 2019 inductee into the National Academy of Medicine.

 

Read more

Previous Global Prize Winners

2021 Global Prize Winner  Bella Kaufman, MD

Bella Kaufman, MD, of Sheba Medical Center in Tel HaShomer, Israel, is the recipient of the 2020 Basser Global Prize Winner. Dr Kaufman is the Director of the Breast Oncology Institute, as well as the President of Sheba Comprehensive Cancer Center at the Sheba Medical Center. She is a founder and leader of the Israeli Consortium for Hereditary Breast Cancer and is an international leader in the breast cancer and BRCA research communities. 


2019 Global Prize Winners — Douglas Easton, PhD, and Antonis Antoniou, PhD

Douglas Easton, PhD, and Antonis Antoniou, PhD, are the recipients of the 2019 annual Basser Global Prize. Easton and Antoniou are both professors in the department of Public Health and Primary Care at the University of Cambridge, and members of the Cancer Research UK Cambridge Centre. Easton’s and Antoniou’s research focuses on genetic susceptibility to common cancers with the goal of identifying and characterizing genetic variants associated with cancer risk, with a particular emphasis on hormone-related cancers.


2018 Global Prize Winner — Dr. Maria Jasin

Maria Jasin, PhD, is the recipient of the 2018 annual Basser Global Prize. Jasin is a member of the Developmental Biology Program at Memorial Sloan Kettering Cancer Center and a professor at the Weill Graduate School of Medical Sciences at Cornell University. Jasin’s research has helped define the roles of BRCA1 and BRCA2 in DNA repair. Her discoveries have led to numerous investigative efforts worldwide, resulting in a greater understanding of how cancer develops and in new therapies that can lengthen the lives of cancer patients.


2017 Global Prize Winner — Dr. Ashok Venkitaraman

The winner of the 2017 Basser Global Prize is Ashok Venkitaraman, MBBS, PhD, the Ursula Zoellner Professor of Cancer Research and director of the Medical Research Council (MRC) Cancer Unit at the University of Cambridge. Dr. Venkitaraman’s laboratory discovered that BRCA2 plays a critical role in repairing the human genome, and has been instrumental in showing how mutations in BRCA2 incite genome instability, accelerating cancer development. This work has provided the scientific basis for assessing cancer risk in people who carry different BRCA2 mutations, and for new treatments for cancers arising in these patients.


2016 Global Prize Winner — Dr. Steven Narod

The winner of the 2016 Basser Global Prize is cancer geneticist Steven Narod, MD, FRCPC, PhD (hon), FRSC, director of the Familial Breast Cancer Research Unit and a senior scientist at the Women’s College Hospital in Toronto, Ontario, Canada. Narod is a world leader in the field of breast and ovarian cancer genetics, who has made significant contributions to the knowledge of how to assess cancer risk and reduce its mortality in BRCA1 and BRCA2 mutation carriers.


2015 Global Prize Winner — Dr. David Livingston

The winner of the 2015 Basser Global Prize is Dr. David Livingston, the Emil Frei Professor of Genetics and Medicine at Harvard Medical School and Chair of the Executive Committee for Research at Harvard’s Dana Farber Cancer Institute. Dr. Livingston has greatly expanded current understanding of how mutations in BRCA1 and BRCA2 can promote cancer development. His goal is to reduce the number of cells in the breast and ovary of BRCA1 mutation-bearing women that manifest a high potential for becoming malignant. “Our objective is to eliminate them by a relatively non-toxic approach and to ensure that they do not accumulate thereafter,” Livingston explains. “If successful, such an approach has the potential to significantly reduce the likelihood of BRCA1 cancer developing in mutation-bearing women.”


2014 Global Prize Winner — Dr. Mary-Claire King

The winner of the 2014 Basser Global Prize was Dr. Mary-Claire King, from the University of Washington in Seattle. Dr. King is known worldwide for her major accomplishments in human genetics research and one of her most noteworthy achievements is the identification of the BRCA1 gene. 2014 marked the 20th anniversary of the identification of the gene. “We’re very excited to honor Dr. King’s accomplishments in BRCA-related research, particularly as this year marks twenty years since the initial cloning of the BRCA1 gene,” said Dr. Susan Domchek, MD. “The identification ofBRCA1 was the first critical step in work to improve outcomes for individuals with inherited susceptibility to breast cancer. Supporting research projects that are similarly devoted to the prevention and treatment of BRCA-related cancers is a primary mission of the Basser Center.” 


2013 Global Prize Winner — Dr. Alan Ashworth

The winner of the inaugural Basser Global Prize in 2013 was Professor Alan Ashworth, FRS, Chief Executive Office of the Institute for Cancer Research (ICR) in London and head of the Gene Function team in the ICR’s Breakthrough Breast Cancer Research Centre. Professor Ashworth has been a pioneer in efforts to develop therapies to target cancer cells that contain BRCA1 and BRCA2 mutations. His lab has been instrumental in the development of PARP inhibitor therapy, drugs which have shown great promise in attacking breast, ovarian, and other cancers among individuals who carry BRCA1/2 mutations. His new research explores mechanisms of drug resistance among BRCA carriers, and the possibility of combing other agents with PARP inhibitors to maximize their effectiveness and discover new methods of treatment.